Enanta Pharmaceuticals, Inc

ENTA Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of ENTA by members of U.S. Congress

Politician Type Traded
Daniel S. Goldman House / D Sale $1,001 - $15,000 Jul 12, 2023
Thomas MacArthur House / R Sale $1,001 - $15,000 May 27, 2015
Thomas MacArthur House / R Purchase $1,001 - $15,000 Mar 20, 2015
ENTA Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ENTA Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ENTA Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in ENTA holdings by institutional investors

Insider Trading

Quarterly net insider trading by ENTA's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $20,000 Nov 14, 2023 Issue: Health Issues
Corporate Lobbying

ENTA Estimated quarterly lobbying spending

Revenue Breakdown

ENTA Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
ENTA Income Statement
ENTA Balance Sheet
ENTA Cash Flow
U.S. Patents

New ENTA patent grants

  • Patent Title: Benzodiazepine derivatives as rsv inhibitors May. 01, 2018
  • Patent Title: Benzimidazole derivatives Sep. 19, 2017
  • Patent Title: Nucleoside and nucleotide derivatives Aug. 15, 2017
  • Patent Title: Deuterated nucleoside/tide derivatives Aug. 01, 2017
  • Patent Title: Hepatitis c virus inhibitors Jun. 13, 2017
  • Patent Title: Nucleoside and nucleotide derivatives Jun. 13, 2017
  • Patent Title: Cyclosporin analogues for preventing or treating hepatitis c infection Jun. 06, 2017
  • Patent Title: Cyclosporin analogues for preventing or treating hepatitis c infection Apr. 11, 2017
  • Patent Title: Cyclosporin analogues for preventing or treating hepatitis c infection Mar. 28, 2017
  • Patent Title: Macrocylic oximyl hepatitis c protease inhibitors Dec. 27, 2016
  • Patent Title: Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives Jan. 26, 2016
  • Patent Title: Cyclosporin analogues for preventing or treating hepatitis c infection Dec. 29, 2015
  • Patent Title: Macrocyclic proline derived hcv serine protease inhibitors Dec. 29, 2015
  • Patent Title: Bismacrocyclic compounds as hepatitis c virus inhibitors Nov. 24, 2015
  • Patent Title: Cyclosporin analogues for preventing or treating hepatitis c infection Oct. 13, 2015
  • Patent Title: Hepatitis c virus inhibitors Oct. 13, 2015
  • Patent Title: Hepatitis c virus inhibitors Sep. 08, 2015
  • Patent Title: 2′allene-substituted nucleoside derivatives Jul. 21, 2015
  • Patent Title: Combination pharmaceutical agents as inhibitors of hcv replication Jun. 23, 2015
  • Patent Title: Linked dibenzimidazole antivirals Apr. 07, 2015
  • Patent Title: Quinoxalinyl derivatives Feb. 24, 2015
  • Patent Title: Quinoxaline-containing compounds as hepatitis c virus inhibitors Feb. 10, 2015
  • Patent Title: Fluorinated tripeptide hcv serine protease inhibitors Jan. 27, 2015
  • Patent Title: Macrocyclic compounds as hepatitis c virus inhibitors Jan. 20, 2015
  • Patent Title: Hepatitis c virus inhibitors Jan. 13, 2015
  • Patent Title: Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives Jan. 06, 2015
  • Patent Title: Hepatitis c virus inhibitors Jan. 06, 2015
  • Patent Title: Processes for the preparation of novel benzimidazole derivatives Dec. 30, 2014
  • Patent Title: [n-me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis c infection Dec. 09, 2014
  • Patent Title: Macrocyclic nucleoside phosphoramidate derivatives Sep. 30, 2014
  • Patent Title: Hepatitis c virus inhibitors Sep. 02, 2014
  • Patent Title: Hepatitis c virus inhibitors Aug. 26, 2014
  • Patent Title: Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors Aug. 19, 2014
  • Patent Title: Hepatitis c virus inhibitors Jul. 22, 2014
  • Patent Title: Tetrazolyl macrocyclic hepatitis c serine protease inhibitors Jul. 22, 2014
  • Patent Title: Hepatitis c virus inhibitors Jul. 15, 2014
  • Patent Title: Hepatitis c virus inhibitors Jun. 24, 2014
  • Patent Title: Hepatitis c virus inhibitors Apr. 22, 2014
  • Patent Title: Hepatitis c virus inhibitors Apr. 15, 2014
  • Patent Title: Cyclosporin analogues Apr. 01, 2014
  • Patent Title: Benzimidazole derivatives Mar. 18, 2014
  • Patent Title: Hepatitis c virus inhibitors Feb. 18, 2014
  • Patent Title: Macrocyclic proline derived hcv serine protease inhibitors Feb. 11, 2014
  • Patent Title: Linked diimidazole derivatives Jan. 28, 2014
  • Patent Title: Antiviral agents Jan. 07, 2014
  • Patent Title: Hepatitis c virus inhibitors Dec. 17, 2013
  • Patent Title: 2′-chloroacetylenyl substituted nucleoside derivatives Nov. 05, 2013
  • Patent Title: Processes for the preparation of 2 fluoro 6-11 bicyclic erythromycin derivatives Oct. 08, 2013
  • Patent Title: Hepatitis c virus inhibitors Aug. 13, 2013
  • Patent Title: Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors May. 17, 2011
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to ENTA from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
ENTA News

Recent insights relating to ENTA

CNBC Recommendations

Recent picks made for ENTA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ENTA

ENTA Analyst Ratings

ENTA Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ENTA Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ENTA stock a Buy, Sell, or Hold?

  • What is the price target for $ENTA stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ENTA Top Shareholders
Shareholder
Shares Held
ENTA Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ENTA stock?

  • Who owns the most shares of $ENTA stock?

  • What funds own $ENTA stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ENTA Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ENTA Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About ENTA

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

  • Address Watertown, MA
  • Market Cap 367.4 million
  • Employees 120
  • Industrial Classification Pharmaceutical Preparations
Back To Top